PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Evinacumab→

Evinacumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1446419-85-7
Molecular formula
C6344H9784N1692O1988S46
Molecular weight
~143000 g/mol
Drug class
Angiopoietin-like protein 3 (ANGPTL3) inhibitorfully human monoclonal antibody
Mechanism of action
Binds ANGPTL3 and inhibits its interaction with lipoprotein lipase and endothelial lipase, increasing triglyceride-rich lipoprotein clearance and reducing LDL cholesterol through LDL-receptor-independent pathways.
Indications / reported uses
  • Adjunct to diet and other LDL-cholesterol-lowering therapies for patients aged 5 years and older with homozygous familial hypercholesterolaemia (HoFH); it is not indicated for general hypercholesterolaemia without HoFH

Sources: US DailyMed — EVKEEZA (evinacumab-dgnb) · FDA — Evinacumab approval for HoFH · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Evinacumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Evinacumab Permitted Daily Exposure (PDE) report (the Evinacumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Evinacumab Occupational Exposure Limit (OEL) report (the Evinacumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.